LPL Financial
ZYNE

LPL Financial’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

LPL Financial’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,563
Closed -$9K – 4603
2022
Q3 		$9K Sell
12,563
-442
-3% -$501 ﹤0.01% 4378
2022
Q2 		$15K Buy
13,005
+400
+3% +$509 ﹤0.01% 4366
2022
Q1 		$26K Buy
12,605
+255
+2% +$606 ﹤0.01% 4108
2021
Q4 		$36K Sell
12,350
-8,709
-41% -$32.2K ﹤0.01% 4257
2021
Q3 		$89K Sell
21,059
-1,519
-7% -$6.78K ﹤0.01% 4170
2021
Q2 		$119K Sell
22,578
-899
-4% -$4.32K ﹤0.01% 4031
2021
Q1 		$109K Buy
23,477
+10,371
+79% +$47K ﹤0.01% 3913
2020
Q4 		$43K Buy
13,106
+1,728
+15% +$6.56K ﹤0.01% 3739
2020
Q3 		$38K Buy
11,378
+515
+5% +$1.89K ﹤0.01% 3457
2020
Q2 		$37K Buy
10,863
+241
+2% +$1.14K ﹤0.01% 3374
2020
Q1 		$41K Buy
+10,622
New +$49.3K ﹤0.01% 3099
2019
Q4 		– Sell
-46,480
Closed -$351K – 3442
2019
Q3 		$351K Buy
46,480
+8,460
+22% +$95.3K ﹤0.01% 2547
2019
Q2 		$515K Buy
+38,020
New +$439K ﹤0.01% 2259

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

LPL Financial's ZYNE Position: Q4 2022 in Review

LPL Financial sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 12,563 shares — an estimated $9K sold.

LPL Financial first reported a position in ZYNE in Q2 2019 and held it in 13 quarters. The position peaked at $515K in Q2 2019. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

  • LPL Financial reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • LPL Financial sold 12,563 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $9K.
  • LPL Financial first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2019 and held it in 13 quarters.
  • LPL Financial's Zynerba Pharmaceuticals, Inc position peaked at $515K in Q2 2019.
  • 50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on LPL Financial's 13F filing for Q4 2022, filed 7 Feb 2023.